SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

Dianna Ng(University of California, San Francisco), Gregory M. Goldgof(University of California, San Francisco), Brian R. Shy(University of California, San Francisco), Andrew G. Levine(University of California, San Francisco), Joanna Balcerek(University of California, San Francisco), Sagar P. Bapat(University of California, San Francisco), John C. Prostko(Abbott Fund), Mary A. Rodgers(Abbott Fund), Kelly E. Coller(Abbott Fund), Sandra Pearce(Abbott Fund), Sergej Franz(Pacific Research Institute), Li Du(Pacific Research Institute), Mars Stone(University of California, San Francisco), Satish K. Pillai(Pacific Research Institute), Alicia Sotomayor-González(University of California, San Francisco), Venice Servellita(University of California, San Francisco), Claudia Sanchez San Martin(University of California, San Francisco), Andrea Granados(University of California, San Francisco), Dustin R. Glasner(University of California, San Francisco), Lucy M. Han(University of California, San Francisco), Kent Truong(University of California, San Francisco), Naomi Akagi(University of California, San Francisco), David N. Nguyen(University of California, San Francisco), Neil M. Neumann(University of California, San Francisco), Daniel Qazi(University of California, San Francisco), Elaine Hsu(University of California, San Francisco), Wei Gu(University of California, San Francisco), Yale Santos(University of California, San Francisco), Brian Custer(Pacific Research Institute), Valerie Green, Phillip Williamson, Nancy K. Hills(University of California, San Francisco), Chuanyi M. Lu(University of California, San Francisco), Jeffrey D. Whitman(University of California, San Francisco), Susan L. Stramer(American Red Cross), Candace Wang(University of California, San Francisco), Kevin Reyes(University of California, San Francisco), Jill Hakim(ZoneOne Pharma (United States)), Kirk Sujishi(University of California, San Francisco), Fariba Alazzeh(University of California, San Francisco), Lori Pham(University of California, San Francisco), Edward C. Thornborrow(University of California, San Francisco), Ching-Ying Oon(University of California, San Francisco), Steve Miller(University of California, San Francisco), Theodore W. Kurtz(University of California, San Francisco), Graham Simmons(University of California, San Francisco), John Hackett(Abbott Fund), Michael P. Busch(University of California, San Francisco), Charles Y. Chiu(University of California, San Francisco)
Nature Communications
September 17, 2020
10.1038/s41467-020-18468-8
Cited by 183Open Access
Full Text

Abstract

Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.

Related Papers

A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu, Dingyu Zhang, Wenling Wang et al.|New England Journal of Medicine|2020|30.3k
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder et al.|Cell|2020|21.3k
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
Zunyou Wu, Jennifer M. McGoogan|JAMA|2020|18k
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
Xiaobo Yang, Yu Yuan, Jiqian Xu et al.|The Lancet Respiratory Medicine|2020|10.7k
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quanxin Long, Bai-Zhong Liu, Haijun Deng et al.|Nature Medicine|2020|3.1k